Earnings Releases·Nov 5, 2026, 4:10 PM ET

Enliven Therapeutics — Third Quarter 2026 Earnings Summary

Reported a net loss of $27.7 million for Q3 2026, widening from $20.1 million in the prior year period, driven by a 54% increase in R&D expenses to $28.0 million and higher G&A costs of $8.0 million.
Strengthened balance sheet with cash, cash equivalents, and marketable securities reaching $884.4 million as of September 30, 2026, providing a projected cash runway into 2030.
Achieved FDA alignment on the final design for the ENABLE-2 pivotal Phase 3 trial for relcobatinib in CML and confirmed the company remains on track to initiate this study before the end of 2026.
Appointed Kristine Ball to the Board of Directors and advanced clinical positioning with relcobatinib data presented at major hematology conferences, highlighting activity against TKI-resistant mutations including T315I.